162 related articles for article (PubMed ID: 36689066)
1. Survival advantage of locoregional and systemic therapy in oligometastatic breast cancer: an international retrospective cohort study (OLIGO-BC1).
Imoto S; Wang K; Bi XW; Liu G; Im YH; Im SA; Sim SH; Ueno T; Futamura M; Toi M; Fujiwara Y; Ahn SG; Lee JE; Park YH; Takao S; Oba MS; Kitagawa Y; Nishiyama M
Breast Cancer; 2023 May; 30(3):412-423. PubMed ID: 36689066
[TBL] [Abstract][Full Text] [Related]
2. Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer.
Fleckenstein J; Petroff A; Schäfers HJ; Wehler T; Schöpe J; Rübe C
BMC Cancer; 2016 Jun; 16():348. PubMed ID: 27255302
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcomes of oligometastatic breast cancer patients treated with curative intent: an updated report.
Nagasaki E; Kudo R; Tamura M; Hayashi K; Uwagawa T; Kijima Y; Nogi H; Takeyama H; Suzuki M; Nishikawa M; Yano S; Kobayashi T
Breast Cancer; 2021 Sep; 28(5):1051-1061. PubMed ID: 33840010
[TBL] [Abstract][Full Text] [Related]
4. Incidence and survival of patients with oligometastatic esophagogastric cancer: A multicenter cohort study.
Kroese TE; Christ SM; van Rossum PSN; Burger MDL; Buijs GS; Mühlematter U; Andratschke N; Ruurda JP; Hüllner M; Gutschow CA; van Hillegersberg R; Guckenberger M
Radiother Oncol; 2022 Aug; 173():269-276. PubMed ID: 35753555
[TBL] [Abstract][Full Text] [Related]
5. Locoregional therapy for oligometastatic cervical cancer: a single-center retrospective study.
Gao H; Wu H; Zhang Y; Chen Z; Qi Z; Wang M; Cheng P
Int J Gynecol Cancer; 2023 Feb; 33(2):198-207. PubMed ID: 36229079
[TBL] [Abstract][Full Text] [Related]
6. [Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients].
Zhang P; Xu BH; Ma F; Li Q; Yuan P; Wang JY; Zhang P
Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):381-4. PubMed ID: 21875471
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological and Treatment-Associated Prognostic Factors in Patients with Breast Cancer Leptomeningeal Metastases in Relation to Tumor Biology.
Griguolo G; Pouderoux S; Dieci MV; Jacot W; Bourgier C; Miglietta F; Firmin N; Conte P; Viala M; Guarneri V; Darlix A
Oncologist; 2018 Nov; 23(11):1289-1299. PubMed ID: 30120164
[TBL] [Abstract][Full Text] [Related]
8. Overall Survival of Patients With Locoregional and Metastatic Breast Cancer: Is the Influence of Baseline Characteristics the Same?
Gomes I; Aguiar P; Miranda A; Nunes C
Anticancer Res; 2019 Sep; 39(9):5135-5142. PubMed ID: 31519625
[TBL] [Abstract][Full Text] [Related]
9. Possible clinical cure of metastatic breast cancer: lessons from our 30-year experience with oligometastatic breast cancer patients and literature review.
Kobayashi T; Ichiba T; Sakuyama T; Arakawa Y; Nagasaki E; Aiba K; Nogi H; Kawase K; Takeyama H; Toriumi Y; Uchida K; Kobayashi M; Kanehira C; Suzuki M; Ando N; Natori K; Kuraishi Y
Breast Cancer; 2012 Jul; 19(3):218-37. PubMed ID: 22532161
[TBL] [Abstract][Full Text] [Related]
10. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
Prat A; Guarneri V; Paré L; Griguolo G; Pascual T; Dieci MV; Chic N; González-Farré B; Frassoldati A; Sanfeliu E; Cejalvo JM; Muñoz M; Bisagni G; Brasó-Maristany F; Urso L; Vidal M; Brandes AA; Adamo B; Musolino A; Miglietta F; Conte B; Oliveira M; Saura C; Pernas S; Alarcón J; Llombart-Cussac A; Cortés J; Manso L; López R; Ciruelos E; Schettini F; Villagrasa P; Carey LA; Perou CM; Piacentini F; D'Amico R; Tagliafico E; Parker JS; Conte P
Lancet Oncol; 2020 Nov; 21(11):1455-1464. PubMed ID: 33152285
[TBL] [Abstract][Full Text] [Related]
11. Classification for long-term survival in oligometastatic patients treated with ablative radiotherapy: A multi-institutional pooled analysis.
Hong JC; Ayala-Peacock DN; Lee J; Blackstock AW; Okunieff P; Sung MW; Weichselbaum RR; Kao J; Urbanic JJ; Milano MT; Chmura SJ; Salama JK
PLoS One; 2018; 13(4):e0195149. PubMed ID: 29649281
[TBL] [Abstract][Full Text] [Related]
12. Increasing survival of metastatic breast cancer through locoregional surgery.
Díaz de la Noval B; Frías Aldeguer L; Ángeles Leal García M; García López E; Díaz Almirón M; Herrera de la Muela M
Minerva Ginecol; 2018 Feb; 70(1):44-52. PubMed ID: 28994557
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of Curative-Intent Treatment for Patients With Breast Cancer Presenting With Sternal or Mediastinal Involvement.
Christopherson K; Lei X; Barcenas C; Buchholz TA; Garg N; Hoffman KE; Kuerer HM; Mittendorf E; Perkins G; Shaitelman SF; Smith GL; Stauder M; Strom EA; Tereffe W; Woodward WA; Smith BD
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(3):574-581. PubMed ID: 30851348
[TBL] [Abstract][Full Text] [Related]
14. Clinical features and prognostic factors for extracranial oligometastatic breast cancer in China.
Lan B; Abudureheiyimu N; Zhang J; Wang C; Jiang S; Wang J; Ma F; Luo Y; Chen S; Xu B; Fan Y
Int J Cancer; 2020 Dec; 147(11):3199-3205. PubMed ID: 32535918
[TBL] [Abstract][Full Text] [Related]
15. Can locoregional treatment of the primary tumor improve outcomes for women with stage IV breast cancer at diagnosis?
Nguyen DH; Truong PT; Alexander C; Walter CV; Hayashi E; Christie J; Lesperance M
Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):39-45. PubMed ID: 22330986
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Modeling in Pathologic N1 Breast Cancer Without Elective Nodal Irradiation After Current Standard Systemic Management.
Yu JI; Park W; Choi DH; Huh SJ; Nam SJ; Kim SW; Lee JE; Kil WH; Im YH; Ahn JS; Park YH; Cho EY
Clin Breast Cancer; 2015 Aug; 15(4):e197-204. PubMed ID: 25957739
[TBL] [Abstract][Full Text] [Related]
17. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
[TBL] [Abstract][Full Text] [Related]
18. Survival and prognostic factors in oligometastatic breast cancer.
van Ommen-Nijhof A; Steenbruggen TG; Capel L; Vergouwen M; Vrancken Peeters MT; Wiersma TG; Sonke GS
Breast; 2023 Feb; 67():14-20. PubMed ID: 36549169
[TBL] [Abstract][Full Text] [Related]
19. A prognostic scoring model for survival after locoregional therapy in de novo stage IV breast cancer.
Kommalapati A; Tella SH; Goyal G; Ganti AK; Krishnamurthy J; Tandra PK
Breast Cancer Res Treat; 2018 Aug; 170(3):677-685. PubMed ID: 29721715
[TBL] [Abstract][Full Text] [Related]
20. Clinical Outcomes and Prognostic Factors of Pathologic N3 Breast Cancer Treated With Modern Standard Treatments.
Yu JI; Park W; Choi DH; Huh SJ; Nam SJ; Kim SW; Lee JE; Kil WH; Im YH; Ahn JS; Park YH; Cho EY
Clin Breast Cancer; 2015 Dec; 15(6):512-8. PubMed ID: 26188791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
